| Literature DB >> 33123790 |
Hubert Nivet1,2, Amandine Crombé1,3, Paul Schuster1,2, Thomas Ayoub4, Laurent Pourriol1,5, Nicolas Favard1,6, Alban Chazot1,7, Florian Alonzo-Lacroix1, Emile Youssof1,8, Alexandre Ben Cheikh1,7, Julien Balique1,9, Basile Porta1,7, François Petitpierre1,10, Grégoire Bouquet1,11, Charles Mastier1,12, Flavie Bratan1,11, Jean-François Bergerot1,13, Vivien Thomson1,7, Nathan Banaste1,14, Guillaume Gorincour15,16.
Abstract
OBJECTIVES: To evaluate the accuracy of diagnoses of COVID-19 based on chest CT as well as inter-observer agreement between teleradiologists during on-call duty and senior radiologists in suspected COVID-19 patients.Entities:
Keywords: COVID-19; Emergency service; Hospital; Polymerase chain reaction; Teleradiology; Tomography, X-ray computed
Mesh:
Year: 2020 PMID: 33123790 PMCID: PMC7594948 DOI: 10.1007/s00330-020-07345-z
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 5.315
Fig. 1Flowchart
Fig. 2Geographic distribution of patients included
Fig. 3Categorisation using the 5-point scale adapted from the SFR. (a) Score of 1: normal chest CT. (b) Score of 2: lung abnormalities but non consistent with any pulmonary infection (showing acute cardiogenic pulmonary oedema with bilateral pleural effusion [black arrowheads]). (c) Score of 3: lung abnormalities consistent with an infection but not SARS-CoV-2 (showing a lobar consolidation [white arrowhead] with acute community-acquired pneumonia). (d) Score of 4: lung lesions compatible with COVID-19 (showing three small rounded central ground-glass opacities in the lower left lobe [white arrowheads]). (e) Score of 5: lung abnormalities strongly suspicious of COVID-19 (showing bilateral peripheral basal-predominant non-rounded ground-glass opacities [white arrowhead])
Fig. 4Diagnostic accuracy measurements of on-call radiologists and inter-observer agreement variation between on-call radiologists and senior radiologists over the eight periods during the inclusion period: (a) number of cases of chest CT (depicted in black [weighted kappas for each step of the study period]) and number of RT-PCR+ patients (depicted in red [prevalence]). Accuracy corresponds to the percentage (from 0 to 1) of correctly classified observations, the p values for weighted kappa indices were all < 0.001; (b, c) diagnostic accuracy measures of on-call radiologists for a score of 4–5 (b) and 5 (c)
Descriptive characteristics of the study population
| Characteristics | No. of patients |
|---|---|
| Age | |
| Mean | 65.6 ± 18.8 |
| Median (range) | 68.4 (18.5–100.1) |
| Gender | |
| Female | 241/513 (47%) |
| Male | 272/513 (53%) |
| Active smoking | |
| No | 359/412 (87.1%) |
| Yes | 53/412 (12.9%) |
| Recent medication with anti-inflammatory drugs | |
| No | 395/418 (94.5%) |
| Yes | 23/418 (5.5%) |
| Significant medical history | |
| No | 151/478 (31.6%) |
| Yes | 327/478 (68.4%) |
| Medical history— | |
| Obesity | 47/478 (9.8%) |
| High blood pressure | 124/478 (25.9%) |
| Cardiovascular diseases | 96/478 (20.1%) |
| Respiratory diseases | 91/478 (19%) |
| Cancer | 39/478 (8.2%) |
| Immunodepression | 19/478 (4%) |
| Renal diseases | 21/478 (4.4%) |
| Neurovascular diseases | 15/478 (3.1%) |
| Neurodegenerative diseases | 29/478 (6.1%) |
| Liver diseases | 4/478 (0.8%) |
| Underlying chronic disease on chest CT | |
| No | 414/513 (80.7%) |
| Yes | 99/513 (19.3%) |
| Chronic diseases on chest CT— | |
| Emphysema | 56/513 (10.9%) |
| Bronchiectasis | 19/513 (3.7%) |
| Cancer | 8/513 (1.6%) |
| Interstitial lung disease | 12/513 (2.3%) |
| Pleural disease | 6/513 (1.2%) |
Data refer to the number of patients with percentage in parentheses, except for age
Diagnostic accuracy measurements of on-call radiologists and senior radiologists
| On-call radiologists | Senior radiologists | |||
|---|---|---|---|---|
| Distribution of radiologists’ scores§ | ||||
| Score | RT-PCR− | RT-PCR+ | RT-PCR− | RT-PCR+ |
| 1 | 94/269 (34.9%) | 9/244 (3.7%) | 100/269 (37.2%) | 8/244 (3.3%) |
| 2 | 40/269 (14.9%) | 2/244 (0.8%) | 52/269 (19.3%) | 2/244 (0.8%) |
| 3 | 67/269 (24.9%) | 8/244 (3.3%) | 74/269 (27.5%) | 9/244 (3.7%) |
| 4 | 46/269 (17.1%) | 41/244 (16.8%) | 34/269 (12.6%) | 33/244 (13.5%) |
| 5 | 22/269 (8.2%) | 184/244 (75.4%) | 9/269 (3.3%) | 192/244 (78.7%) |
| Accuracy measurements for score = 4 or 5§ | ||||
| OR | 35 (20.3–60.2) | 62.2 (35.2–110.1) | ||
| Sensitivity | 0.92 (0.88–0.95) | 0.92 (0.88–0.95) | ||
| Specificity | 0.75 (0.69–0.80) | 0.84 (0.79–0.88) | ||
| PPV | 0.77 (0.73–0.80) | 0.84 (0.80–0.87) | ||
| NPV | 0.91 (0.87–0.94) | 0.92 (0.86–0.95) | ||
| Accuracy measurements for score = 5§§ | ||||
| OR | 34.4 (20.4–58.2) | 106.7 (51.3–221.7) | ||
| Sensitivity | 0.75 (0.69–0.81) | 0.79 (0.73–0.84) | ||
| Specificity | 0.92 (0.88–0.95) | 0.97 (0.94–0.99) | ||
| PPV | 0.89 (0.85–0.93) | 0.96 (0.92–0.98) | ||
| NPV | 0.80 (0.77–0.84) | 0.83 (0.80–0.86) | ||
| Probability of RT-PCR+ §§§ | ||||
| Score | ||||
| 1, 2, or 3 | 9% | 8% | ||
| 4 | 47% | 49% | ||
| 5 | 89% | 95% | ||
Radiological scores correspond to (1) normal, (2) non-infectious findings, (3) infectious findings but not consistent with COVID-19 infection, (4) consistent with COVID-19 infection, (5) typical appearance of COVID-19 infection
NPV negative predictive value, OR odds ratio, PPV positive predictive value
§Data refer to the number of patients with percentages in parentheses
§§OR, sensitivity, specificity, PPV, and NPV are given with 95% confidence interval
§§§Details for the calculation of the probabilities for RT-PCR+, depending on the score for each radiological reading, are given in Supplementary material 2
Inter-observer agreement between first and second radiological readings
| Radiological features | Inter-observer agreement | |
|---|---|---|
| Presence of GGO | 0.79 (0.74–0.85) | < 0.001* |
| Presence of consolidations | 0.63 (0.56–0.70) | < 0.001* |
| Extent of lesions § | 0.77 (0.73–0.81) | < 0.001* |
| Intralobular reticulations | 0.56 (0.48–0.64) | < 0.001* |
| Fibrosis | 0.41 (0.35–0.57) | < 0.001* |
| Radiologists’scores§ | 0.87 (0.84–0.90) | < 0.001* |
Inter-observer agreements are given with 95% confidence interval
GGO ground-glass opacities
§The corresponding radiological variable was an ordinal variable with more than two levels; therefore, weighted kappas were computed rather than classic Cohen kappas
*p < 0.001
Correlation between clinical and radiological features and RT-PCR status or corresponding diagnostic accuracy measurements
| Characteristics | RT-PCR−§ | RT-PCR+§ | OR | Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|---|---|---|---|
| Clinical features | ||||||||
| Time since onset of symptoms | ||||||||
| < 1 week | 148/240 (61.7%) | 115/223 (51.6%) | ||||||
| 1–2 weeks | 80/240 (33.3%) | 102/223 (45.7%) | 1.51 (1.04–2.19) | 0.48 (0.42–0.55) | 0.62 (0.55–0.68) | 0.53 (0.48–0.59) | 0.57 (0.53–0.61) | |
| > 2 weeks | 12/240 (5%) | 6/223 (2.7%) | 0.3 | 0.52 (0.19–1.42) | 0.03 (0.01–0.06) | 0.95 (0.91–0.97) | 0.33 (0.16–0.56) | 0.52 (0.51–0.53) |
| Dyspnoea | ||||||||
| No | 56/269 (20.8%) | 38/244 (15.6%) | 0.16 | |||||
| Yes | 213/269 (79.2%) | 206/244 (84.4%) | 1.42 (0.90–2.24) | 0.84 (0.79–0.89) | 0.21 (0.16–0.26) | 0.49 (0.47–0.51) | 0.59 (0.50–0.68) | |
| Oxygen saturation | ||||||||
| ≥ 95% | 77/195 (39.5%) | 54/191 (28.3%) | ||||||
| 90–95% | 82/195 (42.1%) | 77/191 (40.3%) | 1.66 (1.08–2.53) | 0.72 (0.65–0.78) | 0.40 (0.33–0.47) | 0.52 (0.48–0.55) | 0.61 (0.54–0.67) | |
| < 90% | 36/195 (18.5%) | 60/191 (31.4%) | 2.02 (1.26–3.25) | 0.31 (0.25–0.38) | 0.81 (0.75–0.87) | 0.607 (0.518–0.689) | 0.57 (0.54–0.59) | |
| Cough | ||||||||
| No | 85/269 (31.6%) | 53/244 (21.7%) | ||||||
| Yes | 184/269 (68.4%) | 191/244 (78.3%) | 1.67 (1.12–2.48) | 0.78 (0.73–0.83) | 0.32 (0.26–0.37) | 0.51 (0.48–0.54) | 0.62 (0.54–0.68) | |
| Fever | ||||||||
| No | 109/269 (40.5%) | 34/244 (13.9%) | ||||||
| Yes | 160/269 (59.5%) | 210/244 (86.1%) | 4.21 (2.72–6.51) | 0.86 (0.81–0.90) | 0.41 (0.35–0.47) | 0.57 (0.54–0.59) | 0.76 (0.69–0.82) | |
| Asthenia | ||||||||
| No | 125/269 (46.5%) | 78/244 (32%) | ||||||
| Yes | 144/269 (53.5%) | 166/244 (68%) | 1.85 (1.29–2.65) | 0.68 (0.62–0.74) | 0.46 (0.40–0.53) | 0.54 (0.50–0.57) | 0.62 (0.56–0.67) | |
| Myalgia | ||||||||
| No | 211/269 (78.4%) | 165/244 (67.6%) | ||||||
| Yes | 58/269 (21.6%) | 79/244 (32.4%) | 1.74 (1.17–2.59) | 0.32 (0.27–0.39) | 0.78 (0.73–0.83) | 0.58 (0.51–0.65) | 0.56 (0.53–0.59) | |
| Headache | ||||||||
| No | 228/269 (84.8%) | 200/244 (82%) | 0.5 | |||||
| Yes | 41/269 (15.2%) | 44/244 (18%) | 1.22 (0.77–1.95) | 0.18 (0.13–0.23) | 0.85 (0.80–0.89) | 0.52 (0.42–0.613) | 0.53 (0.51–0.55) | |
| Ear, nose, throat symptoms | ||||||||
| No | 247/269 (91.8%) | 228/244 (93.4%) | 0.6 | |||||
| Yes | 22/269 (8.2%) | 16/244 (6.6%) | 0.79 (0.40–1.54) | 0.07 (0.04–0.10) | 0.92 (0.88–0.95) | 0.42 (0.28–0.58) | 0.52 (0.51–0.53) | |
| Radiological features | ||||||||
| Presence of GGO | ||||||||
| No | 180/269 (66.9%) | 15/244 (6.1%) | ||||||
| Yes | 89/269 (33.1%) | 229/244 (93.9%) | 30.9 (17.3–55.2) | 0.94 (0.90–0.97) | 0.67 (0.61–0.73) | 0.72 (0.68–0.75) | 0.92 (0.88–0.95) | |
| Non-rounded GGO | ||||||||
| Absent | 197/269 (73.2%) | 31/244 (12.7%) | ||||||
| Present | 72/269 (26.8%) | 213/244 (87.3%) | 18.8 (11.8–29.9) | 0.87 (0.82–0.91) | 0.73 (0.67–0.78) | 0.75 (0.71–0.78) | 0.86 (0.82–0.90) | |
| Rounded GGO | ||||||||
| Absent | 238/269 (88.5%) | 162/244 (66.4%) | ||||||
| Present | 31/269 (11.5%) | 82/244 (33.6%) | 3.89 (2.46–6.15) | 0.34 (0.28–0.40) | 0.88 (0.84–0.92) | 0.73 (0.64–0.79) | 0.59 (0.57–0.62) | |
| Presence of consolidation | ||||||||
| No | 196/269 (72.9%) | 92/244 (37.7%) | ||||||
| Yes | 73/269 (27.1%) | 152/244 (62.3%) | 4.44 (3.05–6.44) | 0.62 (0.56–0.68) | 0.73 (0.67–0.78) | 0.68 (0.63–0.72) | 0.68 (0.64–0.72) | |
| Non-rounded consolidation | ||||||||
| No | 217/269 (80.7%) | 172/244 (70.5%) | ||||||
| Yes | 52/269 (19.3%) | 72/244 (29.5%) | 1.75 (1.16–2.63) | 0.29 (0.24–0.36) | 0.81 (0.75–0.85) | 0.58 (0.50–0.65) | 0.56 (0.53–0.58) | |
| Rounded consolidation | ||||||||
| No | 246/269 (91.4%) | 227/244 (93%) | 0.6 | |||||
| Yes | 23/269 (8.6%) | 17/244 (7%) | 0.80 (0.42–1.54) | 0.07 (0.04–0.11) | 0.91 (0.87–0.94) | 0.42 (0.29–0.58) | 0.52 (0.51–0.53) | |
| Subpleural band | ||||||||
| No | 253/269 (94.1%) | 142/244 (58.2%) | ||||||
| Yes | 16/269 (5.9%) | 102/244 (41.8%) | 11.36 (6.45–20.) | 0.42 (0.36–0.48) | 0.94 (0.91–0.97) | 0.86 (0.79–0.91) | 0.64 (0.61–0.66) | |
| Predominant pattern | ||||||||
| None | 150/269 (55.8%) | 11/244 (4.5%) | ||||||
| Consolidation | 57/269 (21.2%) | 32/244 (13.1%) | 0.56 (0.35–0.90) | 0.13 (0.09–0.18) | 0.79 (0.73–0.84) | 0.36 (0.27–0.45) | 0.5 (0.48–0.52) | |
| GGO | 62/269 (23%) | 201/244 (82.4%) | 15.61(10.1–24.1) | 0.82 (0.77–0.87) | 0.77 (0.715–0.818) | 0.77 (0.72–0.80) | 0.83 (0.78–0.86) | |
| Distribution pattern of lesions | ||||||||
| None | 133/269 (49.4%) | 9/244 (3.7%) | ||||||
| Peripheral predominant | 59/269 (21.9%) | 154/244 (63.1%) | 6.09 (4.13–8.98) | 0.63 (0.57–0.69) | 0.78 (0.73–0.83) | 0.72 (0.67–0.77) | 0.7 (0.66–0.74) | |
| Central predominant | 28/269 (10.4%) | 7/244 (2.9%) | 0.25 (0.11–0.59) | 0.03 (0.01–0.06) | 0.90 (0.85–0.93) | 0.2 (0.1–0.36) | 0.50 (0.49–0.52) | |
| Mixed | 49/269 (18.2%) | 74/244 (30.3%) | 1.95 (1.29–2.95) | 0.30 (0.25–0.37) | 0.82 (0.77–0.86) | 0.60 (0.52- 0.68) | 0.564 (0.54–0.59) | |
| Bilateral lesions | ||||||||
| No | 170/269 (63.2%) | 28/244 (11.5%) | ||||||
| Yes | 99/269 (36.8%) | 216/244 (88.5%) | 13.3 (8.3–21.1) | 0.89 (0.84–0.92) | 0.63 (0.57–0.69) | 0.69 (0.65–0.72) | 0.86 (0.81–0.90) | |
| Diffuse lesions | ||||||||
| No | 231/269 (85.9%) | 71/244 (29.1%) | ||||||
| Yes | 38/269 (14.1%) | 173/244 (70.9%) | 14.8 (9.5–23.) | 0.71 (0.65–0.77) | 0.86 (0.81–0.90) | 0.82 (0.77–0.86) | 0.76 (0.73–0.80) | |
| Basal-predominant lesions | ||||||||
| No | 209/269 (77.7%) | 145/244 (59.4%) | ||||||
| Yes | 60/269 (22.3%) | 99/244 (40.6%) | 2.38 (1.62–3.49) | 0.41 (0.34–0.47) | 0.78 (0.72–0.83) | 0.62 (0.56–0.68) | 0.59 (0.56–0.62) | |
| Extent of lesions | ||||||||
| None | 134/269 (49.8%) | 9/244 (3.7%) | ||||||
| Low | 79/269 (29.4%) | 74/244 (30.3%) | 25.9 (12.8–52.6) | 0.96 (0.93–0.98) | 0.50 (0.44–0.56) | 0.64 (0.61–0.66) | 0.94 (0.89–0.97) | |
| Moderate | 46/269 (17.1%) | 115/244 (47.1%) | 7.4 (5.0–10.9) | 0.66 (0.60–0.72) | 0.79 (0.74–0.84) | 0.74 (0.692- 0.79) | 0.72 (0.68–0.76) | |
| High | 10/269 (3.7%) | 46/244 (18.9%) | 6.02 (2.3–12.2) | 0.19 (0.14–0.24) | 0.96 (0.93–0.98) | 0.82 (0.70–0.90) | 0.57 (0.55–0.58) | |
| Intralobular reticulations | ||||||||
| No | 231/269 (85.9%) | 103/244 (42.2%) | ||||||
| Yes | 38/269 (14.1%) | 141/244 (57.8%) | 8.3 (5.4–12.8) | 0.58 (0.51–0.64) | 0.86 (0.81–0.90) | 0.79 (0.73–0.84) | 0.69 (0.66–0.72) | |
| Tree-in-bud micronodules | ||||||||
| No | 209/269 (77.7%) | 230/244 (94.3%) | ||||||
| Yes | 60/269 (22.3%) | 14/244 (5.7%) | 0.21 (0.11–0.39) | 0.06 (0.03–0.09) | 0.78 (0.72–0.82) | 0.19 (0.12–0.29) | 0.48 (0.46–0.49) | |
| Presence of bronchial wall thickening | ||||||||
| No | 194/269 (72.1%) | 227/244 (93%) | ||||||
| Yes | 75/269 (27.9%) | 17/244 (7%) | 0.19 (0.11–0.34) | 0.07 (0.04–0.11) | 0.72 (0.66–0.77) | 0.19 (0.12–0.27) | 0.46 (0.44–0.48) | |
| Distribution of bronchial abnormalities | ||||||||
| None | 194/269 (72.1%) | 227/244 (93%) | ||||||
| Lobar/segmental | 29/269 (10.8%) | 7/244 (2.9%) | 0.24 (0.11–0.57) | 0.03 (0.01–0.06) | 0.89 (0.85–0.93) | 0.19 (0.10–0.35) | 0.50 (0.49–0.51) | |
| Diffuse | 46/269 (17.1%) | 10/244 (4.1%) | 0.21 (0.10–0.42) | 0.04 (0.02–0.07) | 0.83 (0.78–0.87) | 0.18 (0.10–0.30) | 0.49 (0.47–0.50) | |
| Airway secretion | ||||||||
| No | 208/269 (77.3%) | 227/244 (93%) | ||||||
| Yes | 61/269 (22.7%) | 17/244 (7%) | 0.26 (0.14–0.45) | 0.07 (0.04–0.11) | 0.77 (0.72–0.82) | 0.22 (0.14–0.32) | 0.48 (0.46–0.50) | |
| Fibrosis | ||||||||
| No | 253/269 (94.1%) | 193/244 (79.1%) | ||||||
| Yes | 16/269 (5.9%) | 51/244 (20.9%) | 4.18 (2.3–7.6) | 0.21 (0.16–0.26) | 0.94 (0.90–0.97) | 0.76 (0.65–0.84) | 0.57 (0.55–0.58) | |
| Pleural effusion | ||||||||
| Absent | 221/269 (82.2%) | 215/244 (88.1%) | ||||||
| Yes, unilateral | 18/269 (6.7%) | 10/244 (4.1%) | 0.3 | 0.60 (0.27–1.32) | 0.04 (0.02–0.07) | 0.93 (0.90–0.96) | 0.36 (0.21–0.54) | 0.52 (0.51–0.53) |
| Yes, bilateral | 30/269 (11.2%) | 19/244 (7.8%) | 0.3 | 0.67 (0.37–1.23) | 0.08 (0.05–0.12) | 0.89 (0.85–0.92) | 0.39 (0.27–0.52) | 0.52 (0.50–0.53) |
| Adenomegaly | ||||||||
| No | 248/269 (92.2%) | 218/244 (89.3%) | 0.3 | |||||
| Yes | 21/269 (7.8%) | 26/244 (10.7%) | 1.41 (0.77–2.57) | 0.11 (0.07–0.15) | 0.92 (0.88–0.95) | 0.55 (0.42–0.68) | 0.53 (0.59–0.55) | |
§Data refer to number of patients with percentage in parentheses
OR, sensitivity, specificity, PPV and NPV are given with 95% confidence interval
GGO ground-glass opacities, NPV negative predictive value, OR odds ratio, PPV positive predictive value
*p < 0.05; **p < 0.005; ***p < 0.001 (corresponds to χ2 or Fisher test)
p values in bold correspond to significant associations between clinical or radiological features and RT-PCR status
Regarding variables with more than two levels, the p value in italics corresponds to the p value considering all its levels. The p values below are based on the Fisher or χ2 test for this variable that was dichotomised according to the level of the line